Abstract Library

#4601 Pembrolizumab combined with cisplatin or carboplatin and etoposide in treatment naïve advanced Merkel cell carcinoma (MCC): The phase II PANDORA Trial

Introduction: MCC is a rare and aggressive skin neuroendocrine tumour with high metastatic potential and mortality. Therapeutic options in metastatic/unresectable MCC are based on immunotherapy or platinum-based chemotherapy. However, a subgroup of patients (pts) has primary immunoresistance disease, so it would be important discover active upfront combinations. PANDORA trial [NCT 06086288] is an open-label, multicentre, single-arm phase II trial evaluating the activity and safety of pembrolizumab (PEM) combined with platinum-based chemotherapy as 1st line treatment in pts with metastatic, unresectable or recurrence MCC. Supported in part by a research grant from Investigator-Initiated Studies Program of MSD.

Conference:

Presenting Author: Oldani S

Authors: Oldani S, Morano F, Cingarlini S, Di Giacomo A, Borghesani M,

Keywords: Pembrolizumab, clinical trial, Merkel cell carcinoma, chemio-immunotherapy,

#3482 PANDORA-2 protocol - Intervention study to improve quality of life in patients with small (≤2 cm) non-functional pancreatic neuroendocrine tumors

Introduction: Current guidelines changed the treatment strategy for small (≤2cm) non-functioning pancreatic neuroendocrine tumors (NF-pNET) from tumor resection to an active surveillance strategy. The previous PANDORA-1 (2021) study showed excellent clinical outcomes after a median follow-up of 17 months, where 89% of patients had pNETs without any tumor growth and only 3% of patients had tumor growth leading to a resection. Despite these results, the quality of life (QoL) was decreased at baseline and during follow-up. Furthermore, there was suboptimal adherence to the advised surveillance protocol.

Conference:

Presenting Author: Chen J

Authors: Chen J, Heidsma C, Engelsman A, Nieveen van Dijkum E,

Keywords: neuroendocrine, pancreatic, quality of life, ≤2 cm, non-functional, protocol,

#2204 Pancreatic Neuroendocrine Tumors: Analysis of Prognostic Factors After Surgical Resection in a Single Centre

Introduction: Pancreatic neuroendocrine tumors (PNET) are rare, heterogeneous and challenging neoplasms. Surgical resection is the only curative treatment. Recurrence can occur even after years. Diagnosis of malignancy is difficult so further studies are necessary to identify prognostic criteria.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Blanco L, Dopazo C, Pando E, Caralt M, Puértolas N,

Keywords: PNETS, Prognosis,

#1100 Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A/P16) Polymorphisms and Risk of Pancreatic Neuroendocrine Tumors

Introduction: Pancreatic neuroendocrine tumors (PNETs) represent only 1% of all pancreatic neoplasms by incidence, but 10% by prevalence. Family history of cancer is the only established risk factor so far. The impact of germline genetic variability on PNET risk is poorly understood.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Canzian F

Authors: Campa D, Rizzato C, Capurso G, Delle Fave G, Gazouli M,

Keywords: pancreatic neuroendocrine tumor, p16, cdkn2a, genetic polymorphisms, SNP, association, susceptibility,